The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …

Background This is the second update of the review first published in the Cochrane Library
(2010, Issue 2) and later updated (2014, Issue 9).

A first-in-human phase I trial of Vvax001, an alphavirus-based therapeutic cancer vaccine
against human papillomavirus (HPV)-induced cancers was performed assessing …

CD103-positive tissue resident memory-like CD8 + T cells (CD8CD103 TRM) are associated
with improved prognosis across malignancies, including high-grade serous ovarian cancer …

Objective Adult granulosa cell tumors (aGCTs) represent a rare, hormonally active subtype of
ovarian cancer that has a tendency to relapse late and repeatedly. Current serum hormone …

Simple Summary Identification of human cancer-reactive CD8+ T cells is crucial for the
stratification of patients for immunotherapy and determination of immune-therapeutic effects. Here…

Epithelial Ovarian cancer (EOC) is the most lethal gynecological malignancy and has limited
curative therapeutic options. Immunotherapy for EOC is promising, but clinical efficacy …

Background Recent studies suggest neoadjuvant immune checkpoint blockade (ICB) may
be more efficacious than adjuvant treatment in mismatch repair deficient (MMRd) cancers. …

Introduction/Background Adult granulosa cell tumours (aGCT) are rare ovarian malignancies,
molecularly characterized by a single somatic c.402C>G mutation in FOXL2. Recurrent …

Identification of human cancer-reactive CD8+ T cells is crucial for stratification of patients for
immunotherapy and determination of immune-therapeutic effects. To date, these T cells …